Navigation Links
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Date:3/10/2008

New 2.25 mm Diameter Stent Now Available in Europe, Asia and Latin America

ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm version of its XIENCE(TM) V Everolimus Eluting Coronary Stent System, offering physicians a smaller stent based upon the proven efficacy, positive safety results and excellent deliverability of XIENCE V. The addition of the 2.25 mm stent to the XIENCE V portfolio gives physicians access to a wider range of stent sizes for treating a variety of patient types.

"Lesions in small vessels tend to be more complex and challenging to treat, so it's important to have a drug eluting stent with proven clinical benefits that can be easily delivered to the diseased area of the vessel," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "With XIENCE V 2.25 mm, physicians now have access to a smaller stent that combines these critical attributes with the positive safety outcomes we have seen with XIENCE V. These outcomes include low rates of reintervention in the diseased vessel, low rates of heart attack and death, and low rates of vessel renarrowing following treatment."

The 2.25 mm version of the XIENCE V stent will be launched immediately in the majority of European markets and select countries in Asia and Latin America. In addition to the 2.25 mm stent, XIENCE V is available in stent diameters of 2.5 mm, 2.75 mm, 3.0 mm, 3.5 mm and 4.0 mm for lesions 28 mm or shorter.

Coronary artery disease (CAD) occurs when arteries become narrow due to plaque buildup, restricting blood flow to the heart. Approximately 30 to 40 percent of CAD lesions occur in vessels equal to or less than 2.5 mm in diameter.

XIENCE V is the only drug eluting stent to demonstrate superiority over another drug eluting stent in a randomized clinical trial. In t
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
2. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
3. Abbott Announces 10.8 Percent Increase in Quarterly Dividend
4. On Valentines Day, Abbott Urges Women to Take Heart With Launch of Faces of Heart Disease Exhibit to Raise Heart Health Awareness
5. Abbott Goes Red to Educate Bay Area Women About Heart Disease
6. Abbott to Present at Merrill Lynch Healthcare Conference
7. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
8. Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2007 Earnings
9. Cookie Johnson and Abbott Bring I Stand With Magic: Campaign to End Black AIDS to Los Angeles to Educate African-American Women on HIV/AIDS
10. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
11. The Magic Johnson Foundation and Abbott Expand Focus of Campaign to End Black AIDS to African-American Women in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 29, 2014 A ... the peer-reviewed journal Lipids in Health and Disease ... Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ranked ... to SPINS scan data, the product was shown ... other omega-3 products in the marketplace. The goal ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The ... named a 2014 ASAE Power of A ... public awareness campaign to encourage everyone age six months ... , ASAE recognized NFID for its power to enrich ... and action among consumers and professionals about the importance ...
(Date:7/29/2014)... 29, 2014 The Eleventh Annual Business ... concluded with the $10,000 prize being presented to Ambika ... ) , The 11th Annual Summit was held on ... who can bring innovative products and services for the ... to have had such excellent array of young companies ...
(Date:7/29/2014)... July 29, 2014 Oxnard dentists , ... Dental Art Institute in Oxnard and Woodland Hills, Calif., regularly ... out or been removed due to dental disease. , However, ... two prosthodontists (experts in restoring and replacing teeth) want the ... implant specialists to perform their dental work and of not ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 "Acceptance, Recognition, ... man who faced his own demons and wants other men ... intended life partner left. A month later, he had no ... longer pay. When Raymond approached the government for assistance, the ... a two-year counselling program. But this approach didn’t get to ...
Breaking Medicine News(10 mins):Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:Oxnard Dental Implant Experts Warn of Infections Around Dental Implants 2Health News:Oxnard Dental Implant Experts Warn of Infections Around Dental Implants 3Health News:Oxnard Dental Implant Experts Warn of Infections Around Dental Implants 4Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2
... Randy Dotinga HealthDay Reporter , MONDAY, April 11 ... talking on the phone and enjoying a cappuccino, know that ... things at once forever. In fact, new research finds ... multitask, possibly because they can,t refocus as well after getting ...
... Reinberg HealthDay Reporter , MONDAY, April 11 (HealthDay ... emissions of heart-harmful microscopic particles by 98 percent, which could ... suggests. The very tiny particles found in diesel engine ... caused by air pollution, but "if we use these particle ...
... California Institute for Quantitative Biosciences (QB3) has entered into ... its efforts to convert bioscience innovation into a driver ... Deloitte, which provides consulting, audit, tax and financial advisory ... help QB3 develop an "innovation ecosystem," bringing together the ...
... attending sexual health clinics in Gothenburg found that just four ... they had the disorder. However, a third of those who ... symptoms at a follow-up visit, reveals a thesis from the ... a specialist in skin and sexually transmitted infections at the ...
... from Tufts Medical Center researchers published today finds that a ... few other options because their disease has developed resistance to ... the study is the first published report showing that ... mouse model of the disease and is effective against human ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, April 11 ... is showing promise in keeping a deadly type of cancerous ... the most common type of cancerous brain tumor. It,s also ... after diagnosis, said Dr. Isaac Yang, a neurosurgeon at University ...
Cached Medicine News:Health News:Multitasking Just a Bit Tougher for Older People: Study 2Health News:Multitasking Just a Bit Tougher for Older People: Study 3Health News:Emissions Trap Cuts Harmful Diesel Pollution 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 3Health News:QB3, Deloitte collaborate to drive California bioscience innovation 2Health News:Recurring genital problems could be herpes 2Health News:New drug shows potential for treatment-resistant leukemia 2Health News:Brain Tumor Vaccine Shows Promise in Early Trials 2Health News:Brain Tumor Vaccine Shows Promise in Early Trials 3
(Date:7/28/2014)... Ala. , July 28, 2014 ... J. Tipton , Ph.D., President and CEO of ... the Controlled Release Society (CRS) for the 2014-2015 ... annual meeting on July 12 in ... 40 countries.  The Controlled Release ...
(Date:7/28/2014)...  Houston dentist , Dr. Behzad ... with Invisalign. With access to this increasingly popular ... straightened without feeling self-conscious in the process. Invisalign ... types of braces, but patients who choose Invisalign ... better support for their oral health and comfort ...
(Date:7/28/2014)... 2014 Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and operator ... centers in China , today announced ... declared a special cash dividend of US$0.30 per ordinary ... the Company,s outstanding ordinary shares. The total expense for ...
Breaking Medicine Technology:Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2Concord Medical Declares Special Dividend 2
... trial conducted at Evergreen Healthcare shows that a new form ... improves the quality of life for patients and reduces the ... walking. Evergreen was the only site in the ... Dr. C. Warren Olanow, a Fellow of the American Academy ...
... April 20, 2012  CVS Caremark Corporation (NYSE: ... Wednesday, May 2, 2012, at 8:30 a.m. (EDT) with ... financial results. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) ... will be broadcast simultaneously through the Investor Relations portion ...
Cached Medicine Technology:Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 3CVS Caremark Corporation to Hold First Quarter 2012 Conference Call 2
Red Rubber Robinson Catheters (Latex)...
Silver Foley Catheter 3-way...
Silicone-Coated Foley Catheter 2-Way...
Silicone Foley Catheters 2-Way (Pediatric)...
Medicine Products: